2017;35(suppl): Abstr. # 3531. Antonia SJ, López-Martin JA, Bendell J, et al: Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): A multicentre, open -label, phase 1/2 trial. Lancet Oncol.